PORTLAND, Ore.

俄勒冈州波特兰

,

，

July 29, 2026

2026年7月29日

/PRNewswire/ --

/美通社/ --

Trace Biosciences, Inc.

痕量生物科学公司

, a clinical-stage biotechnology company developing nerve-targeted imaging agents, today announced it has received a strategic investment from

，一家开发神经靶向成像剂的临床阶段生物技术公司，今日宣布已获得来自的战略投资

Axogen, Inc.

Axogen公司

(NASDAQ:

（纳斯达克：

AXGN

AXGN

), the global leader in surgical solutions for restoration of peripheral nerve function, as its technology continues to advance through clinical development. The investment is part of Trace's Series A financing round with additional investors expected to join.

），作为恢复外周神经功能手术解决方案的全球领导者，其技术正通过临床开发不断取得进展。此次投资是Trace公司A轮融资的一部分，预计还将有其他投资者加入。

Nerve Trace is a near-infrared fluorescence imaging technology designed to provide direct, real-time visualization of nerves during surgery, including nerves that are otherwise obscured from view by surrounding tissue. The technology enables two clinically significant applications. First, by rendering nerves visible in real time, it allows surgeons to identify and avoid nerves that would otherwise be obscured from view during a broad range of surgical procedures.

Nerve Trace 是一种近红外荧光成像技术，旨在为手术中神经的直接、实时可视化提供支持，包括那些被周围组织遮挡而无法直接观察到的神经。该技术可实现两项具有临床意义的应用。首先，通过实时显示神经，它使外科医生能够在广泛的手术操作中识别并避开原本会被遮挡的神经。

Second, in cases where a nerve has already been injured, it allows surgeons to localize and assess the nerve with greater precision, supporting more effective surgical repair. Trace's lead candidate, Nerve Trace Dx, received FDA clearance of its Investigational New Drug (IND) application in December 2025 and has began its Phase I clinical trial evaluating Nerve Trace's safety and feasibility in surgical patients.

其次，在神经已经受损的情况下，它使外科医生能够更精确地定位和评估神经，从而支持更有效的手术修复。Trace公司的主要候选产品Nerve Trace Dx于2025年12月获得美国食品药品监督管理局（FDA）对其新药临床试验申请（IND）的批准，并已启动I期临床试验，以评估Nerve Trace在手术患者中的安全性和可行性。

Proceeds from the investment will support Trace's Phase II and III clinical trials toward a New Drug Application (NDA)..

投资所得将用于支持Trace的新药申请（NDA）二期和三期临床试验。

'We're pleased to welcome Axogen, a company that shares our commitment to protecting nerve function, as a strategic partner in this next phase of our growth. This investment strengthens our ability to advance Nerve Trace through the clinical work ahead, giving surgeons visibility into nerves they've not been able to see before,' said .

“我们很高兴欢迎Axogen成为我们下一增长阶段的战略合作伙伴，该公司与我们同样致力于保护神经功能。此次投资增强了我们推进Nerve Trace完成后续临床研究的能力，使外科医生能够清晰地观察到以往无法看到的神经。”

Connor Barth, Ph.D., Co-Founder and CEO of Trace Biosciences.

康纳·巴斯博士，Trace Biosciences 联合创始人兼首席执行官。

'Improving nerve care starts with being able to see the nerve. You can't treat what you can't see,' said

“改善神经护理始于能够看到神经。你无法治疗看不见的东西，”说道

Michael Dale, President and CEO of Axogen, Inc.

Axogen公司总裁兼首席执行官迈克尔·戴尔

'This investment in Trace's technology is directly aligned with our mission of making restoration of peripheral nerve function an expected standard of care. Giving surgeons the ability to see nerves in real time, whether to protect them or to treat them, is foundational to that mission.'

“对Trace技术的这项投资与我们的使命直接契合，即让周围神经功能的恢复成为预期的护理标准。赋予外科医生实时观察神经的能力，无论是为了保护神经还是治疗神经，都是实现这一使命的基础。”

About Trace Biosciences

关于Trace Biosciences

Trace Biosciences is a clinical-stage biotechnology company pioneering nerve-targeted imaging technologies for surgery. Founded by leaders in imaging, chemistry, and translational medicine, Trace is developing a new class of small-molecule imaging agents designed to make nerves visible and measurable in clinical settings.

Trace Biosciences 是一家处于临床阶段的生物技术公司，致力于开创用于手术的神经靶向成像技术。由成像、化学和转化医学领域的领导者创立，Trace 正在开发一类新型小分子成像剂，旨在使神经在临床环境中可见且可测量。

The company's mission is to make safe, precise surgery a reality by making nerves visible in every operating room..

公司的使命是通过让神经在每一间手术室中都清晰可见，使安全、精准的手术成为现实。

For more information, visit

更多信息，请访问

www.trace-bio.com

www.trace-bio.com

About Axogen, Inc

关于 Axogen 公司

Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers.

Axogen（AXGN）是一家专注于周围神经再生与修复技术的科学研究、开发及商业化的领先企业。Axogen 的员工满怀热忱，致力于为外科医生和医疗保健提供者提供创新、经临床验证且具有经济效用的修复解决方案，从而为周围神经损伤患者恢复神经功能并提升生活质量创造机会。

Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

周围神经为全身的运动和感觉信号提供传导通路。每天都有人因遭受创伤性损伤或接受外科手术而影响周围神经的功能。周围神经的物理性损伤，或周围神经无法正确重新连接，可能导致肌肉或器官功能丧失、感觉缺失，或引发疼痛。

Axogen's product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™..

Axogen的产品组合包括Avance®（无细胞神经同种异体移植物-arwx）、Avance®神经移植物、Axoguard神经连接器®、Axoguard神经保护器®、Axoguard HA+神经保护器™、Axoguard神经帽®以及Avive+软组织基质™。

For more information, visit

更多信息，请访问

www.axogeninc.com

www.axogeninc.com

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements, including statements regarding the terms and expected timing of the financing, the use of proceeds, the progress of clinical trials, and the anticipated benefits of the collaboration between Trace Biosciences and Axogen. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied.

本新闻稿包含前瞻性陈述，包括有关融资条款及预期时间、资金用途、临床试验进展以及Trace Biosciences与Axogen之间合作的预期效益的陈述。这些陈述受风险和不确定性的影响，可能导致实际结果与明示或暗示的结果存在重大差异。

Trace Biosciences undertakes no obligation to update these statements except as required by law..

Trace Biosciences 除法律要求外，不承担更新这些陈述的义务。

Media Contact:

媒体联系人：

[email protected]

[email protected]

SOURCE Trace Biosciences

来源：Trace Biosciences

21

二十一

%

%

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示